Cargando…

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma

Ibrutinib has clear efficacy for activated B-cell-like diffuse large B cell lymphoma (ABC-DLBCL) in previous clinical researches. However, the resistance of Ibrutinib has limited its therapeutic benefit and the potential mechanism remains unclear. This study was aimed to identify potential candidate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiazheng, Huang, Yan, Zhang, Yun, Wen, Jingjing, Chen, Yanxin, Wang, Lingyan, Jiang, Peifang, Hu, Jianda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904539/ https://www.ncbi.nlm.nih.gov/pubmed/33629212 http://dx.doi.org/10.1007/s12032-021-01470-5

Ejemplares similares

Identification of Early Recurrence Factors in Childhood and Adolescent B-Cell Acute Lymphoblastic Leukemia Based on Integrated Bioinformatics Analysis
por: Huang, Yan, et al.
Publicado: (2020)

Loss of MiR-155 Sensitizes FLT3-ITD(+)AML to Chemotherapy and FLT3 Inhibitors via Glycolysis Blocking by Targeting PIK3R1
por: Wang, Lingyan, et al.
Publicado: (2023)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
por: He, Yizi, et al.
Publicado: (2019)

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
por: T Low, Justin, et al.
Publicado: (2020)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
por: Xue, Chao, et al.
Publicado: (2020)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib
por: Paydaş, Semra, et al.
Publicado: (2021)

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR
por: Jin, Jia, et al.
Publicado: (2020)

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma
por: Fan, Qian, et al.
Publicado: (2016)

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
por: Zheng, Xiaohui, et al.
Publicado: (2014)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib
por: Pehlivan, Umur Anil, et al.
Publicado: (2021)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
por: Hodkinson, Brendan P., et al.
Publicado: (2020)

miR-4284 and miR-4484 as Putative Biomarkers for Diffuse Large B-Cell Lymphoma
por: Tamaddon, Gholamhossein, et al.
Publicado: (2016)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib
por: Shouse, Geoffrey, et al.
Publicado: (2018)

Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Petrillo, Alessandra, et al.
Publicado: (2022)

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
por: George, Bhawana, et al.
Publicado: (2020)

Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma
por: Chen, Yi, et al.
Publicado: (2019)

Effect of nucleolin on adriamycin resistance via the regulation of B‐cell lymphoma 2 expression in Burkitt's lymphoma cells
por: Mei, Xuqiao, et al.
Publicado: (2019)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy
por: Fox, Lucy C., et al.
Publicado: (2018)

Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters
por: Filho, Eduardo Henrique Cunha Neves, et al.
Publicado: (2023)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wilson, Wyndham H., et al.
Publicado: (2021)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
por: Ying, Carol Y., et al.
Publicado: (2013)

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
por: Rossi, Alessandra, et al.
Publicado: (2021)

Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia
por: Chen, Yanxin, et al.
Publicado: (2020)

The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Ziel-Swier, Lotteke J. Y. M., et al.
Publicado: (2022)

hsa-miR-429 targets CBX8 to promote cell apoptosis in diffuse large B-cell lymphoma
por: Liang, Yan, et al.
Publicado: (2021)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Expression and clinical significance of miR-23a and MTSS1 in diffuse large B-cell lymphoma
por: Xu, Mengwei, et al.
Publicado: (2018)

MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
por: Sun, Jing-Ran, et al.
Publicado: (2019)

Pre‐miR‐27a rs895819 polymorphism and risk of diffuse large B‐cell lymphoma
por: Tang, Weiyan, et al.
Publicado: (2019)

Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma
por: Yan, Shufang, et al.
Publicado: (2022)

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma
por: Lee, Ki Rim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s9fvdmops56kl7u6kn18tk1rj4